Mavacamten is primarily used in the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition characterized by the thickening of the heart muscle, which can obstruct blood flow. It works by selectively inhibiting cardiac myosin, a protein involved in muscle contraction, thereby reducing the excessive contractility of the heart muscle. This helps alleviate symptoms such as shortness of breath, chest pain, and fatigue, improving overall cardiac function and quality of life for patients. Its targeted mechanism offers a promising therapeutic approach for managing this complex cardiovascular disorder.